Dr Reddy's surged in trade after Nomura upgraded the stock by 2.5%, citing biosimilar milestones

Mon 28 Sep 2026

Heard on Live television at 12:52:35 IST.

• Nomura maintained a bullish call on Dr Reddy's with a 2.5% upgrade.
• Analyst cited US FDA biological facility clearance and Acept biosimilar decision due 18 December 2026 as key triggers.
• Drug is used to treat inflammation; management called it a potential game changer.
• Company planning first wave launch across 50+ countries with November 2020 relaunch guidance and FY27 sales volume of 6-7 million pens expected.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.